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Abstract
PT73 (TM) is a dried, heat-inactivated bacterial biomass used as a feed material produced from an
Escherichia coli K-12 strain, which was genetically modiﬁed to overproduce threonine. The recipient
organism E. coli MG 1655 is considered to be safe. The traits introduced in the ﬁnal modiﬁed strain
E. coli FERM BP-10942 are mainly limited to the overproduction of threonine. No full-length antibiotic
resistance genes or other sequences of concern remain in the modiﬁed strain. In conclusion, the EFSA
Panel on Additives and Products or Substances used in Animal Feed (FEEDAP): does not identify risks
for human and animal health or the environment from this biomass regarding the genetic modiﬁcation
of the strain. The proposed recommended use level for dairy cows (8% PT73 (TM) of feed dry matter
(~ 7% in complete feed)) and salmonids (13%) is considered safe for these target animals. The
conclusion form dairy cows could be extended to other ruminants (from the beginning of rumination).
Complete feed for pigs for fattening may contain up to 10% PT73 (TM). The toxicological data indicate
effects of PT73 (TM) on blood coagulation and liver, which are considered to be adverse. As a
consequence, the FEEDAP Panel is unable to conclude on the safety for the consumer of products
derived from animals receiving feed containing PT73 (TM). PT73 (TM) is not considered a skin/eye
irritant but should be considered as a potential skin and respiratory sensitiser. Moreover, any exposure
of users to dust from the product via the inhalation route should be considered a serious risk. The
FEEDAP Panel considers that substitution of PT73 (TM) for other protein-rich feed materials will not
adversely affect the environment.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: heat-inactivated biomass, Escherichia coli, safety, nutritional value, genetically modiﬁed
microorganism
Requestor: Competent Authority of France
Question number: EFSA-Q-2008-412b
Correspondence: feedap@efsa.europa.eu
EFSA Journal 2017;15(8):4936www.efsa.europa.eu/efsajournal
Panel members: Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos,
Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli, Gerhard Flachowsky, J€urgen Gropp, Boris
Kolar, Maryline Kouba, Marta Lopez-Alonso, Secundino Lopez Puente, Alberto Mantovani, Baltasar
Mayo, Fernando Ramos, Guido Rychen, Maria Saarela, Roberto Edoardo Villa, Robert John Wallace and
Pieter Wester.
Note: The content of this opinion may be edited once a decision on conﬁdentiality is received from
the European Commission, in accordance with Article 30(2) of Regulation (EC) No 1829/2003.
Acknowledgements: The Panel wishes to thank the members of the former GMO Panel Working
Group on Genetically Modiﬁed Microorganisms: Niels Bohse Hendriksen, Michael Gasson, Nickolas
Panopoulos and Christoph Tebbe for the preparatory work on this scientiﬁc output.
Suggested citation: EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used
in Animal Feed), Rychen G, Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Cocconcelli PS,
Flachowsky G, Gropp J, Kolar B, Kouba M, Lopez-Alonso M, Lopez Puente S, Mantovani A, Mayo B,
Ramos F, Saarela M, Villa RE, Wallace RJ, Wester P, Brantom P, Herman L, K€arenlampi S, Aguilera J,
Galobart J, Holczknecht O and Chesson A, 2017. Scientiﬁc Opinion on the safety and nutritional value
of a dried killed bacterial biomass from Escherichia coli (FERM BP-10942) (PT73 (TM)) as a feed
material for pigs, ruminants and salmonids. EFSA Journal 2017;15(8):4936, 22 pp. https://doi.org/
10.2903/j.efsa.2017.4936
ISSN: 1831-4732
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
PT73 (TM) biomass of Escherichia coli
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2017;15(8):4936
Summary
Following a request from the Competent Authority of France, the Panel on Additives and Products
or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on subject.
PT73 (TM) is a dried, killed bacterial biomass produced by fermentation of the genetically modiﬁed
Escherichia coli strain FERM BP-10942. In this strain, genes for the overexpression of enzymes for
L-threonine production are introduced. The molecular characterisation of the strain does not indicate a
safety concern. No DNA sequences of concern including those conferring antibiotic resistances are
present in the production strain.
The maximum safe level for dairy cows would be 7% PT73 (TM) of feed dry matter ( 6% in
complete feed). This value could be extended to other ruminants (from the beginning of rumination).
Complete feed for pigs for fattening may contain up to 10% PT73 (TM). PT73 (TM) is safe for
salmonids up to a dietary concentration of 13%.
The toxicological data indicate effects of PT73 (TM) on blood coagulation and liver, which are
considered to be adverse. Since the causative agent and mechanism of these effects is unknown,
there is no way of determining whether residues exist in animal products sufﬁcient to cause similar
effects in consumers. As a consequence, the FEEDAP Panel is unable to conclude on the safety for the
consumer of products derived from animals receiving feed containing PT73 (TM).
PT73 (TM) is not considered a skin/eye irritant but should be considered as a potential skin and
respiratory sensitiser. The FEEDAP Panel considers that due to the endotoxin content any exposure of
users to dust from the product via the inhalation route should be considered a risk.
PL73 (TM) does not contain viable recombinant cells but contains trace amounts of recombinant
DNA. No risks associated with a theoretically possible horizontal gene transfer of this recombinant DNA
to environmental bacteria have been identiﬁed. The FEEDAP Panel considers that substitution of PT73
(TM) for other protein-rich feed materials will not adversely affect the environment.
Since the risks identiﬁed do not relate to the genetic modiﬁcation but to the product itself
(biomasses from fermentation with E. coli and potentially other Gram-negative bacteria), the
Panel recommends that similar non-genetically modiﬁed products used as a feed material should also
be assessed for safety.
PT73 (TM) biomass of Escherichia coli
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1829/20031 establishes the rules governing the Community authorisation of
genetically modiﬁed food and feed. In particular, Article 17(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with that Article.
On 7 August 2008, the European Food Safety Authority (EFSA) received from the French
Competent Authority an application for authorisation of a dried killed genetically modiﬁed (GM)
bacterial biomass from Escherichia coli (FERM BP-10942) (PT73 (TM)) submitted by Ajinomoto
Eurolysine SAS2 within the framework of Regulation (EC) No 1829/2003 on GM food and feed.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Article 18(6) of that Regulation and thus will be part of the EFSA overall opinion in
accordance with Article 18(5).
According to Article 17 of Regulation (EC) No 1829/2003, EFSA shall determine whether the feed
complies with the conditions laid down in Article 16. EFSA shall deliver an opinion on the safety for
humans, animals and the environment and on the nutritional quality of the dried killed bacterial
biomass (PT73 (TM)) produced by the genetically modiﬁed E. coli (FERM BP-10942) when used as a
feed material under the conditions described in Section 3.5.1.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier3 in support of the authorisation request for the use of PT73 (TM) as a feed material.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as peer-reviewed scientiﬁc papers and other scientiﬁc reports to deliver the present output.
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and nutritional value of PT73
(TM) is in line with the principles laid down in the relevant guidance documents: Guidance on the
assessment of microbial biomasses for use in animal nutrition (EFSA FEEDAP Panel, 2011a), Guidance
on the risk assessment of genetically modiﬁed microorganisms and their products intended for food
and feed use (EFSA GMO Panel, 2011), Technical guidance: Tolerance and efﬁcacy studies in target
animals (EFSA FEEDAP Panel, 2011b), Guidance for establishing the safety of additives for the
consumer (EFSA FEEDAP Panel, 2012a) and Guidance on studies concerning the safety of use of the
additive for users/workers (EFSA FEEDAP Panel, 2012b).
3. Assessment
The current application concerns the use of an inactivated E. coli biomass (PT73 (TM)), which is a
by-product of L-threonine production by fermentation using a genetically modiﬁed strain of E. coli K-12
(FERM BP-10942). It is intended to be used as a feed material for pigs, ruminants and salmonids.
The data contained in the dossier relates to different batches from pilot scale production to full
scale industrial production of the biomass PT73 (TM). It also contains some data relative to another
biomass produced by a previous strain of E. coli (PT73 (THR)). When data from this biomass has been
used in the assessment, this will be indicated in the opinion.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1.
2 Ajinomoto Eurolysine SAS. 153, rue de Courcelles, 75817 PARIS Cedex 17 (France).
3 Application EFSA-GMO-FR-2008-59. FEED dossier reference: FAD-2008-035.
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3.1. Manufacturing process4
The fermentation process has been described in detail in the dossier with full information on all of
the substances used during the production process.
After removal of the L-threonine, the solids are concentrated and dried. The resulting biomass
powder is granulated/pelleted, cooled and sieved to remove broken pellets and ﬁne dust which are
recycled to pellet production.
An antifoaming agent is added during the fermentation which results in residues in the ﬁnal feed
material (see Sections 3.3.2 and 3.6.4).
3.2. Characterisation of the genetically modiﬁed strain E. coli FERM
BP-109425
The microorganism of which PT73 (TM) is made is a genetically modiﬁed derivative of E. coli K-12,
deposited at the Japanese International Patent Organism Depositary and National Institute of
Advanced Industrial Science and Technology with accession number FERM BP-10942. The strain was
identiﬁed as E. coli K-12 by molecular serotyping of the rfb cluster and the fliC gene and comparison
with databases. Antibiotic susceptibility was tested using agar diffusion against of 31 antibiotics
including 8 out of the 10 antibiotics recommended by EFSA (EFSA FEEDAP Panel, 2012a,b) for E. coli.
Minimum inhibitory concentration (MIC) values were provided. The strain was found sensitive to all
antibiotics tested. Polymerase chain reaction (PCR) analysis indicated the absence of virulence genes
including genes encoding enterotoxins, Shiga toxins, and adhesion and invasion factors in the genome
of E. coli FERM BP-10942. The strain was found not to contain plasmids, transposons, sex factors or
prophages.
The recipient strain E. coli MG 1655 is a derivative of E. coli K-12 obtained after ultraviolet (UV)
irradiation followed by mutagenic treatment (Bachmann, 1987). E. coli K-12 is a Gram-negative, non-
sporulating bacterium. It is well-characterised and its safety (non-pathogenicity) has been reviewed
extensively (Gorbach, 1978). The genome of E. coli K-12 is fully sequenced (Hayashi et al., 2006).
The dossier contains detailed and sufﬁcient information regarding the origin and function of
the different genetic elements introduced in the production strain, the genetic modiﬁcation process
and the genetic and phenotypic traits introduced.
3.3. Characterisation of the ﬁnal feed material
3.3.1. Composition
The applicant has provided information on the composition of six batches of the product. One of
the batches derived from a small scale pilot production (produced in 2006), four from industrial scale
production (produced in 2009 and 2013) and one industrial scale produced in 2015. Four additional
batches produced in 2015 were used for the analysis of dry matter, crude protein (CP), antifoaming
agent residues, purine and pyrimidine bases and endotoxin content. The results for the industrial scale
batches produced in 2009, 2013 and 2015 are considered in detail below.
The product is characterised by its high content of CP (~ 84%). The chemical composition of the
four industrial and the pilot scale batches is shown in Table 1.
Table 1: Chemical composition of the industrial batches of PT73 (TM) produced in 2009 and 2013
(4 batches) and 2015 (1 batch). Values in % of dry matter (DM) (except DM: % of the
product)
2009–2013(a) 2015(b)
Average Range Average Range
Dry matter 93.2 88.6–96.8 96.1 95.6–96.6
Ash 4.9 1.3–8.0 1.1 –
4 This section has been amended following the conﬁdentiality claims made by the applicant on the basis of Article 30(1) of
Regulation (EC) No 1829/2003.
5 This section has been amended following the conﬁdentiality claims made by the applicant on the basis of Article 30(1) of
Regulation (EC) No 1829/2003.
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The total amino acid content of the four industrial batches (produced in 2009 and 2013) was
76.6%, (DM basis) (Table 2), coming mainly from bacterial protein, with free amino acids (other than
threonine) representing only a minor fraction (0–0.4%, total approximately 4%). The amounts of the
main amino acids revealed little variation between the batches. Amino acid analyses made with one
batch produced in 2015 gave essentially the same results.
Ammonium N (as NH4) ranged between approximately 0.8% and 2% and ‘true protein’ (calculated
by subtracting ammonia N from total N) was 82.8 for the four industrial batches. Low levels of nitrates
(≤ 0.03%) and nitrites (≤ 0.06%) were detected, while betaine levels were 0–0.18%. Slightly lower
values for ammonium N (0.6%) were obtained for the batch produced in 2015.
Three of the industrial batches (2009) were analysed for levels of DNA and RNA which were
0.0003–0.0043% and 0.002–0.0049%, respectively. The levels of nucleotides (purine and pyrimidine
monophosphates) varied between 1.29% and 3.57%. Purine and pyrimidine bases were not measured
in the industrial batches produced in 2009 and 2013. Values for the ﬁve batches produced in 2015
showed that purine bases were on average 1.4% DM while pyrimidine bases were on average 1.0%.
Analysis of biogenic amines (putrescine, cadaverine, histamine, spermidine, agmatine, spermine,
tyramine and phenylethylamine) in the three industrial batches produced in 2009 had the following
results (expressed on DM basis): 0.003–0.007% putrescine, 0.011–0.032% cadaverine and
0.0015–0.0031% spermidine while the other amines were below the respective limits of quantiﬁcation
(LOQ). Similar values were obtained with the batches produced in 2013 and 2015.
2009–2013(a) 2015(b)
Average Range Average Range
Crude protein 86.1 82.8–89.6 82.3 81.1–83.1
Crude fat 8.1 7.76–8.6 8.5 –
Starch 1.0 – – –
Sugars 0.8 – – –
(a): Dry matter, ash, crude protein and crude fat were determined in four batches. Starch and sugars were determined in one
batch.
(b): Dry matter and crude protein were determined in ﬁve batches. Ash and crude fat were determined in one batch.
Table 2: Amino acids in the four industrial scale batches of PT73 (TM) produced in 2009 and 2013.
Values are given as % of dry matter
Amino acid Average Range
Glutamic acid/glutamine 9.62 8.90–10.49
Aspartic acid/asparagine 7.88 7.38–8.36
Threonine 7.27 6.71–7.75
Leucine 6.91 6.66–7.22
Alanine 5.78 5.37–6.22
Arginine 4.89 4.61–5.20
Lysine 4.84 4.29–5.28
Valine 4.54 4.16–5.07
Glycine 3.85 3.57–4.15
Isoleucine 3.83 3.62–4.03
Phenylalanine 3.35 3.17–3.50
Tyrosine 3.01 2.80–3.13
Serine 2.96 2.82–3.24
Proline 2.60 2.39–2.88
Methionine 2.01 1.91–2.09
Histidine 1.65 1.45–2.04
Tryptophan 1.14 1.10–1.20
Cystine 0.46 0.41–0.49
Total amino acids 76.58 72.35–81.83
PT73 (TM) biomass of Escherichia coli
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(8):4936
Total crude fat, measured in four batches (2009 and 2013) showed a mean value of 7.76%. The
most abundant fatty acids were C14:0 (0.42% in DM), C16:0 (1.99%), C16:1cis (0.40%) and C18:1cis
(0.72%), typical of Gram-negative bacteria. A similar pattern was seen in the analysis of one batch
produced in 2015.
Organic acids (acetic, propionic, butyric, lactic, formic, pyruvic and isovaleric acid) were analysed in
the four industrial batches. The sum of organic acids (% as is) was around 0.5–0.9%. One of the
batches produced in 2015 was also analysed and the total amount of organic acids was 0.03%.
The most signiﬁcant inorganic substances detected were sulfates and sodium, but for some of them
there was considerable variation between the batches (Table 3).
Analysis of one industrial batch produced in 2015 showed levels of water soluble vitamins expected
for a material deriving from bacterial biomass. Vitamins A, D and E, provitamin A and other
carotenoids were below levels of quantiﬁcation.
The contents of endotoxins (lipopolysaccharides (LPS)) were analysed in duplicate in the ﬁve batches
of the product produced during 2015. Values ranged between 2.3 9 105 and 1.0 9 106 EU/g.6
3.3.2. Impurities
Heavy metals (Pb, Hg and Cd) and arsenic were measured in four batches and found to be well
below the maximum authorised limits for feed materials.7 Residues of pesticides, dioxins and dioxins
plus dioxin-like polychlorinated biphenyls (PCBs) were analysed in two batches and found to be below
the LOQ for pesticides and below the maximum levels set by Directive 2002/32/EC for dioxins and
dioxins plus dioxin-like PCBs.
Residues of the antifoaming agent added during the fermentation were analysed in the ﬁnal feed
material. Data in three batches of PT73 (TM) (produced in 2015) showed that the levels of
antifoaming agent were approximately 15 g/kg.
The microbiological analysis of the four batches showed that Salmonella, staphylococci,
Clostridium perfringens, sulﬁte-reducers, coliforms and faecal streptococci were below the limit of
detection. Yeasts were detected in one batch (< 40 CFU/g) and ﬁlamentous fungi were detected in
three batches (80–260 CFU/g). All fermentation substrates are obtained with a speciﬁcation that meets
European Union (EU) legislation on maximum limits for aﬂatoxin B1, and consequently, no analyses
were performed in the ﬁnal product.
The absence of viable cells of E. coli FERM BP-10942 from the product PT73 (TM) was
demonstrated by (i) liquid culturing, allowing the growth of stressed cells, followed by selective plating
in three batches of the ﬁnal product, each tested in triplicate; and (ii) direct selective plating of two
batches of the ﬁnal product (20 replicates per batch). In both liquid and solid culture methods, 1 g of
the inactivated fermentation product was tested.
The presence of recombinant DNA from E. coli FERM BP-10942 was investigated in 13 batches of
PT73 (TM) product by PCR, capable of amplifying a 454 bp fragment of recombinant DNA. Results
Table 3: Content of minerals and trace elements of four industrial scale batches of PT73 (TM)
produced in 2009 and 2013. Unless otherwise stated values are given as % dry matter
Average Range
Sodium 0.86 0.16–1.78
Potassium 0.03 0.02–0.06
Calcium 0.005 0.002–0.009
Magnesium 0.005 0.003–0.01
Chlorides 0.05 0.02–0.09
Sulfates 1.36 0.87–2.71
Phosphates 1.09 0.02–3.58
Iron (mg/kg product) 123 84–180
Copper (mg/kg product) 1.2 1.0–1.3
6 1 EU corresponds to 0.1 ng of the international reference endotoxin standard coming from Escherichia coli (amount present in
105 bacteria).
7 Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed.
OJ L 140, 30.5.2002, p. 10.
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indicated the presence of trace amounts of DNA from the production strain in about eight out of the
13 batches tested. Another PCR assay, targeting a 930 bp fragment, did not show any ampliﬁcation.
3.3.3. Physical properties
PT73 (TM) is a brown pelleted product (pellet size ~ 6–8 mm diameter) with an apparent bulk
density of 638 kg/m3. The particle size determination (laser diffraction) and the dusting potential
measurement (rotating drum technique) were carried out on the residual ﬁne dust fraction obtained by
sieving the pellets. This fraction (< 1,400 lm) represented 6.3% w/w of the total product. It was
shown that 15% of that sample had a particle size below 45 lm. The results of dustiness obtained for
the ﬁne powder fraction were recalculated to the original biomass pellets. Values showed that the
inhalable, thoracic and respirable fraction were 1,092, 471 and 48 mg/kg product which would result
in a classiﬁcation of PT73 (TM) as of low-moderate dusting potential.
3.3.4. Storage life
In a stability trial, PT73 (TM) (one batch) was stored for 12 months under three different
conditions (25°C/60%, 40°C/30% and 40°C/60%). Moisture content, water activity, crude nutrients,
ammonium N/ammonia and biogenic amines were monitored. Additionally, microbiological quality was
assessed by aerobic count, and counts of counts of Staphylococcus aureus, Salmonella,
Bacillus cereus, yeast, ﬁlamentous fungi and Enterobacteriaceae. Pellet quality was also measured. The
parameters measured showed no deterioration of PT73 (TM) in any of the conditions studied.
PT73 (TM) was included in a complementary feed for dairy cows at a rate of 13.3%. Samples were
stored at 5, 25 or 40°C with a relative humidity (RH) of 60% for three months in punctured nylon bags
to simulate practical storage conditions. The parameters evaluated included gross composition,
biogenic amines, microbiological counts and physical properties. No signiﬁcant differences were
observed in the parameters tested after storage.
The above ﬁndings were supported by a study in pig feed with PT73 (THR) with levels of inclusion
of 5% and 20% up to 6 months.
3.4. Safety aspects of the genetically modiﬁed strain E. coli FERM
BP-10942
The strain E. coli FERM BP-10942, from which the product is made, was conﬁrmed to have been derived
from the recipient strain E. coli MG 1655. The recipient strain E. coli K-12S B-7 is considered to be safe.
The traits introduced are well known and do not raise safety concern. Southern or PCR analysis
conﬁrmed the absence of all full-length antibiotic resistance genes used during the entire genetic
modiﬁcation. Bioinformatic analysis did not show any biologically relevant similarity to known allergens
or toxins for any of the putative peptides that might be produced from the open reading frames
spanning the junctions between the Mu sequences and genomic DNA. Therefore, the product PL73
(TM), obtained from E. coli BP-10942, does not give rise to any safety concern with regard to the
genetically modiﬁed strain from which it is made.
3.5. Nutritional characterisation of PT73 (TM)
3.5.1. Conditions of use
The product PT73 (TM) is intended to be used as a feed material, a source of protein for pigs for
fattening, ruminants (for meat and milk production from the beginning of rumination) and salmonids.
The maximum use levels recommended in complete feed are 12% for pigs and 13% for salmonids (or
replacement of 20% of ﬁsh meal in a complete diet containing 65% ﬁsh meal). For ruminants, the
maximum recommended level is 7.3% biomass DM in complete feed dry matter.
3.5.2. Nutritional studies
In order to show the nutritional value of the biomass under assessment, the applicant submitted a
series of in vitro/in vivo digestibility studies and long-term feeding trials with the target animals. Not all
of the studies were performed with the biomass PT73 (TM). Some nutritional studies were made with
the biomass PT73 (THR) also derived from cells of E. coli K-12 modiﬁed to increase threonine
production. As nutrient composition shows the PT73 (THR) biomass is sufﬁciently similar to PT73 (TM)
PT73 (TM) biomass of Escherichia coli
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that results obtained with PT73 (THR) can be considered in the assessment of PT73 (TM) (Table 4).
Since some essential nutrient characteristics of PT73 (THR) are inferior to those of PT73 (TM) (i.e. CP,
sum of amino acids, energy, sulfate), tolerable dietary levels derived from studies with PT73 (THR) can
be taken as a conservative estimate for PT73 (TM).
3.5.2.1. In vitro digestibility
A battery of in vitro tests simulating ruminal and/or gastrointestinal conditions was used to estimate
the digestibility of different fractions of PL73 (TM). The results showed organic matter digestibility
(81–84%), rumen protein solubility (2830% of CP), rumen escape/undegraded protein (34–67% of
CP), CP digestibility in monogastrics (63%).
3.5.2.2. In vivo digestibility PT73 (THR)
Pigs
The study was conducted on 2 9 9 pigs (barrows, body weight at start 28–30 kg) for 9 weeks to
determine the apparent ileal and faecal digestibility of PT73 (THR). The study was designed according
the ‘difference technique’. The standard diet was mainly based on wheat, barley, soybean meal, wheat
middlings and tapioca and was supplemented with 0.25 g chromium oxide as inert marker per kg feed.
The test diet contained 15% PT73 (THR), which was ‘contaminated’ with another E. coli biomass
(PL73 (LYS)) most probably at a level between 5% and 10%.
The apparent ileal (faecal) digestibility coefﬁcients were 82 (90)% for DM, 84 (91)% for CP, and 91
with a range from 76% to 95% for the sum of amino acids. Sulfate is apparently largely absorbed.
Digestible energy was found to be 19, net energy 10 MJ/kg DM.
Sheep
In a digestion trial, two groups of six sheep (wethers, body weight at start 70–100 kg) were
offered 900 g basal diet (chopped hay, sugar beet pulp and molasses)/day and 1,000 g test diet (75%
standard diet, 25% PT73 (THR))/day), respectively. The apparent digestibility was measured for CP
with 93%, for crude fat with 89% and for nitrogen free extract with 96%.
The digestibility coefﬁcient of CP from PT73 (THR) is in the same range as that of other protein-rich
feedstuffs like rape seed or soybean expeller.
Rainbow trout
The study was conducted on a total of 90 rainbow trout (Oncorhynchus mykiss) (body weight at
start about 100 g) divided in six replicates (three per treatment of 15 ﬁsh each). Fish were fed by
hand to apparent satiation a basal diet (ﬁsh meal (60%), gelatinised wheat starch (24%), ﬁsh oil
(12%), supplemented with chromic oxide (1%) as an inert marker) and the test diet consisting of 70%
basal diet and 30% PT73 (THR), respectively. Faeces were collected for the second week of a 2-week
Table 4: Main composition parameters of the biomasses PT73 (TM) and PT73 (THR) (on % dry
matter basis)
Composition parameter PT73 (TM)(a) PT73 (THR)(b)
Dry matter 87.3 88.9
Crude protein 86.1 77.4
Ammonium N 0.98 0.95
Sum of total amino acid 76.6 62.0
Crude fat 8.1 7.5
Crude ﬁbre – 0.7
Crude ash 4.9 5
Potassium 0.03 0.27
Sodium 0.86 0.34
Chlorides 0.05 0.87
Sulfates 1.36 2.99
Phosphates 1.09 3.7
(a): Average of four batches (Table 1).
(b): One batch.
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feeding period. The apparent digestibility of CP from PL73 (THR) was 87%. Digestible energy was
17 MJ/kg PT73 (THR) DM.
3.5.2.3. Feeding studies in target animals – Dairy cows
Studies with PT73 (TM)
Study 1
To investigate the maximum incorporation rate of PT73 (TM) in diets for ruminants, a study was
conducted on a total of 64 dairy cows (Dutch Holstein-Friesian type). After a 5-week adaptation period
to the total mixed ration (TMR), four groups of 16 cows equalised for milk production, feed intake and
lactation stage, were fed diets containing 0 (control), 50, 100 and 150 g of PT73 (TM) DM per kg TMR
DM, referred to as RPT00, RPT05, RPT10 and RPT15, respectively. The experimental period lasted
8 weeks (56 days).
The basal TMR consisted of grass silage, forage maize silage, grass seed hay and a concentrate. The
concentrate consisted of increasing amounts of PT73 (TM) (0%, 14.2%, 28.9% and 43.2%) at the
expense of maize gluten meal, soybean meal, palm oil and urea. It contained 7.6 MJ net energy and
about 40% CP. The content of intestinal digestible protein was calculated with 262, 260, 259 and 256 g
for the concentrates with increasing amounts of PT73 (TM). All rations were offered ad libitum. Animals
were fed at a non-limiting protein level (around 20% CP in ration DM), ensuring that any effect of the
inclusion of PT73 (TM) in the ration is caused by characteristics other than its feeding value for protein.
Throughout the experiment, feed intake and milk yield were recorded daily for each animal. Each
week, milk was sampled and concentrations of fat, protein, lactose and urea were determined. In
week 0, 2, 4 and 8, individual blood samples were taken to evaluate the effect of PT73 (TM)
prothrombin time, packed cell volume and haemoglobin, total leukocytes, neutrophilic, basophilic and
eosinophilic granulocytes, lymphocytes, monocytes, erythrocytes and thrombocytes as well as alkaline
phosphatase, total protein, albumin, cholesterol, phospholipids, inorganic phosphorus, non-esteriﬁed
fatty acids, triglycerides, transferrin, 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol.
Feed intake, milk production and milk composition data were analysed with the restricted maximum
likelihood method. Blood values were analysed by an analysis of variance (ANOVA).
In week 6 of the experimental period, one cow of RPT05 had to be removed because of a large
hematoma from the mammary vein and one cow of RPT15 died of liver abscess.
No signiﬁcant effects were observed on feed intake, milk yield and milk composition between the
different treatment groups (Table 5). Feed intake decreased linearly over the whole experimental period
including the 5-week adaptation period, with a slight tendency for recover intake during the last 3 weeks.
Table 5: Feed intake, milk production (only data of week 8 of the experimental period are given)
and composition and some blood parameters of cows fed graded levels of PT73 (TM)(1)
RPT00 RPT05 RPT10 RPT15
PT73 (TM) calculated (g/kg DM(2)) 0 50 100 150
PT73 (TM) actual (g/kg DM) 0 54 109 167
DM intake (kg/day) 22.1 22.2 22.0 22.2
PT73 (TM) intake (kg DM/day) 0.0 1.2 2.4 3.7
Milk yield (kg/day) 35.5 36.8 35.3 35.8
FPCM(3) (kg/day) 34.6 36.0 34.5 35.4
Protein (g/kg milk) 32.6 34.5 36.0 36.6
Protein (kg/day) 1.15 1.26 1.26 1.30
Fat (g/kg milk) 38.6 38.2 37.6 38.2
Fat (kg/day) 1.36 1.38 1.30 1.35
Lactose (g/kg milk) 47.2 46.6 45.8 46.2
Lactose (kg/day) 1.67 1.72 1.61 1.65
Urea (mg/100 mL milk) 37 37 35 39
Cholesterol (mmoL/L blood) 5.0 4.8 4.8 4.8
Phospholipids (mmoL/L blood) 3.1 2.9 3.0 2.9
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Haematology did not show signiﬁcant differences between groups except a slight but not dose-
related changes on thrombocytes and segmented and basophilic granulocytes.
There was a signiﬁcant reduction in plasma vitamin D metabolites. Plasma 25-hydroxycholecalciferol
levels in the PT groups were signiﬁcantly lower than in the control group. However, plasma cholesterol
was not inﬂuenced by the treatment.
Study 2
In a study with 24 dairy cows, PT73 (TM) was tested at four levels (50, 100, 150 and 200 g of DM
per kg of ration DM) in comparison to a zero control treatment. This resulted in ﬁve experimental
treatments. An incomplete Latin square design was used with three 4-week periods. The cows
received the ration as TMR of which the DM was based on 16.7% grass silage, 34.5% forage maize
silage and 48.8% concentrate, the concentrate containing the varying levels of PT73 (TM). The
FEEDAP Panel has considerable reservations about the experimental design selected, since not all cows
were subject to all treatments, the experimental period was short (4 weeks/treatment) and the
potential effect of the biomass was measured against reducing performance (reduced milk yield).
Moreover, with increasing inclusion of PT73 (TM), the intake of CP increased (from 17.6% to 26.3% CP
in DM of the diets (TMR) with 0% and 20% PT73 (TM), respectively. High-protein feed materials
should be compared on an isonitrogenous basis. Therefore, this study was not further considered.
Study 3
To investigate the maximum incorporation rate of PT73 (TM) in diets for ruminants, a study was
conducted on a total of 24 dairy cows (Dutch Holstein-Friesian type) Six groups of cows were formed.
In each group, four cows at a comparable stage of lactation and with a comparable milk yield were
selected. Cows within each group were randomly distributed over the four experimental treatments in
period I. The 21-week experiment was set up as an incomplete Latin square design with four
treatments and three periods. After a 5-week adaptation period (3 weeks TMR and commercial
concentrate), the cows were offered four diets containing 0 (control), 26.6, 53.3 and 80.0 g of PT73
(TM) DM per kg complete feed DM, referred to as PT00, PT27, PT53 and PT80, respectively. The
experimental periods lasted 5, 5 and 6 weeks.
The basal TMR consisted of grass silage, forage maize silage, grass seed hay and a concentrate.
The concentrate consisted of increasing amounts of PL73 (TM) (0%, 6.7%, 13.3% and 20.0%) at the
expense of soybean meal, palm oil and urea. It contained 7.53–7.60 MJ net energy for lactation and
23.3–24.4% CP. The content of intestinal digestible protein was calculated with 150, 163, 170 and
173 g for the concentrates with increasing amounts of PT73 (TM). All rations were offered ad libitum
(24 kg DM complete feed/day).
Throughout the experiment, feed intake and milk yield were recorded daily for each animal. In the
fourth and ﬁfth week of each experimental period, milk was sampled and concentrations of fat,
protein, lactose and urea were determined.
The effects of treatments on feed intake, milk production and milk composition were analysed by
ANOVA. Effects of the level of incorporation were tested by polynomial regression analyses.
In the ﬁrst week of the second experimental period, one cow broke its leg and was replaced by
other one. During statistical analyses the data for Period I for this cow were deﬁned as missing values.
Daily feed intake of the diets was lower (22.4–22.9 kg DM) than the projected feed intake of 24 kg
DM per cow used for ration formulation. No statistical differences in DM intake and intake of Net
energy for lactation (NEL) between treatments. For treatment PT27, the intake of CP was signiﬁcantly
lower than for treatments PT00 and PT80.
No differences between treatments were observed in production of milk (32.4–32.7 kg/day), milk
fat, milk lactose and milk urea. A tendency was observed for a treatment effect on milk protein
concentration (p = 0.07). Polynomial analyses showed a signiﬁcant positive linear effect of rate of
incorporation of PT73 (TM) on milk protein concentration (p = 0.02).
RPT00 RPT05 RPT10 RPT15
25-Hydroxycholecalciferol, (nmol/L blood) 104a 96b 98a,b 94b
(1): No statistics were provided for FPCM, protein, fat and lactose yield (kg/day).
(2): Dry matter.
(3): Fat (40 g/kg) and protein (33 g/kg) standardised milk.
a,b: Means within a row with different superscript letters are signiﬁcantly different (p ≤ 0.05).
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Conclusions for dairy cows and ruminants
Commonly used protein-rich ingredients in rations for high-yielding dairy cattle can be replaced by
biomass PT73 (TM) when using the present guidelines for dairy cow nutrition in practice, the chemical
composition and the nutritive value of PT73 (TM) and other ration ingredients.
The FEEDAP Panel concludes that the biomass PT73 (TM) can be used in formulating diets for
ruminants as any other protein-rich feed material at the level recommended by the applicant (8% in
complete feed DM).
3.5.2.4. Feeding studies in target animals – Pigs for fattening
Studies with PT73 (THR)
Study 1
A total of 40 pigs (20 gilts, 20 boars, 32 kg body weight (bw) at start) were fed for 9 weeks diets
containing 0%, 5%, 10%, 15% and 20% PT73 (THR), respectively. Four individually housed pigs per
sex were allocated to each group and fed a grower diet for 36 days and a ﬁnisher diet for 27 days.
The diets consisted mainly of maize, tapioca, soybean meal and wheat middlings. The PT73 (THR) was
included mainly at the expense of soybean meal, the diets were calculated to be isocaloric. K2CO3 was
supplemented to prevent dietary electrolyte imbalances in the diets containing the PT73 (THR). Dietary
CP content in the diets increased with increasing amounts of the PT73 (THR) (for the diets with 0%,
5%, 10%, 15% and 20% PT73 (THR), CP levels of 18.5%, 19.15, 20.4%, 21.6% and 22.0% in the
grower and 14.9%, 16.0%, 17.0%, 18.0% and 19.2% in the ﬁnisher diet were found, respectively).
The FEEDAP Panel has reservations regarding the formulation of the experimental diets; high protein
feed materials should be compared on an isonitrogenous basis.
Body weight, feed and water intake, and faeces consistency were recorded in regular intervals. At
day 54, blood samples were taken for haematology and routine blood chemistry.8 At post-mortem,
kidneys, liver, spleen and the pars oesophagea and fundus region of the stomach were examined, and
the weight of the kidneys, liver, spleen and empty stomach was recorded. Data were analysed using
an ANOVA with sex and treatment as factors. Differences between treatments were evaluated by least
signiﬁcant difference (LSD) test.
Overall performance during the trial was good (control group body weight gain, 1,086 g/day, feed
intake 2.46 kg/day, feed to gain 2.27). These parameters did not signiﬁcantly differ between groups
for the entire 9-week period, but in the grower period, all PT73 (THR) groups had a signiﬁcantly
higher feed to gain ratio, and body weight gain of the 15% and 20% PT73 (THR) groups was
signiﬁcantly less than that of the control.
Water and water to feed intake ratio were not signiﬁcantly affected by the PT73 (THR) diets.
Faeces consistency of the 15% and 20% PT73 (THR) groups was signiﬁcantly reduced in the three
other groups (grower phase and complete experimental period).
Clinical blood chemistry parameters were not affected by treatment with the exception of a dose-
related increase in bilirubin levels which were signiﬁcantly higher in the 15% and 20% PT73 (THR)
groups, compared to the control group. No signiﬁcant differences were observed with regard to
haematological parameters, with the exception of the content of haemoglobin and the packed cell
volume that were slightly higher in the 10% and 15% groups compared to the control group. As no
dose–response relationship was observed, these increases are considered to be incidental.
Body weight at slaughter, back fat thickness and meat percentage of the carcass were not affected
by increasing dietary PT73 (THR). Organ weights were not affected by treatment with the exception of
absolute kidney weights which were slightly but signiﬁcantly increased at the 10%, 15% and 20%
levels compared to the control group. These ﬁndings may be related to increasing renal urea excretion
with increasing dietary protein.
Study 2
Four groups of 64 pigs (4 replicates with 8 boars and 4 replicates with 8 gilts, about 30 kg bw at
start) were fed for 10 weeks (6 weeks grower diets and 4 weeks ﬁnisher diets) diets containing 0%,
6%, 9% and 12% PT73 (THR), respectively. The control diet was based on wheat, barley, maize,
8 Including: prothrombine time, alkaline phosphatase, total protein, albumin, total bilirubin, cholesterol, inorganic phosphate and
phospholipids.
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tapioca, soybean meal, peas and wheat middlings. PT73 (THR) was incorporated in the diets at the
expense of soybean meal and peas.
The diets were formulated to be equal in net energy content and to meet the requirements for the
levels of apparent ileal digestible lysine, methionine and cysteine, threonine and tryptophan. The diets
containing PT73 (THR) were supplemented with NaHCO3 and K2CO3 to prevent dietary electrolyte
imbalances. Dietary CP was analytically shown to be approximately equal in grower (18.7–18.9%) and
ﬁnisher diets (17.0–17.2%). General health, individual body weight and feed intake (per pen) were
monitored thorough the study. At the end of the study, the pigs were killed and carcass weight, meat
percentage and backfat and muscle thickness were measured. Data were analysed by ANOVA.
Differences between means were evaluated by LSD test.
Data of the control group (feed intake 2,272 g/day, weight gain 932 g/day and feed to gain 2.44)
are indicative of a well-designed and conducted study. Feed intake, average daily gain and feed to
gain ratio were not signiﬁcantly affected by increasing amounts of PT73 (THR) up to 12% in the diet in
either the grower or ﬁnisher phase.
Body weight at slaughter and carcass characteristics (carcass weight, carcass percentage, meat
percentage of the carcass, back fat and muscle thickness) were not markedly affected by the
experimental treatments. However, backfat thickness (control value 16.3 mm) was increased
(signiﬁcantly for the groups with 6% and 9% PT73 (THR)).
Conclusions for pigs for fattening
The FEEDAP Panel concludes that PT73 (THR) can be used in formulating diets for pigs for
fattening up to a level of 10% on the basis of the apparent increased sensitivity of animals in the
grower phase. The Panel considers that this conclusion applies to PT73 (TM). Particular consideration
should be given to the electrolyte balance of diets containing PT73 (TM).
3.5.2.5. Feeding studies in target animals – rainbow trout
Study with PT73 (THR)
A total of 15 replicates (tanks) of 40 rainbow trout (O. mykiss) each (body weight at start 99 g)
were allocated to ﬁve experimental treatments. Fish were fed for 12 weeks diets in which 10%, 20%,
40% and 60% of total ﬁsh meal (65.2% in the control group) was replaced by PT73 (THR),
corresponding to actual levels of PT73 (THR) in feed of 6.6%, 13.1%, 26.3% and 39.4%. Fish were
fed twice a day by hand near to visual satiety. Water was supplied from natural springs at a constant
temperature of 17  1°C. CP of the control diet was 50.5% in DM, the diets with 6.6%, 13.1%,
26.3% and 39.4% PT73 (THR) contained 50.3%, 50.0%, 50.2% and 48.9% CP in DM. Gross energy
(17.6 MJ/kg DM in the control diet) rose with increasing amounts of PT73 (THR) up to 22.1 MJ/kg DM
in the 39.4% PT73 (THR) diet. Every 3 weeks ﬁsh were kept unfed for 24 h, counted and weighed in
groups. At termination of the trial, blood was sampled from 15 ﬁsh per replicate 18 h after the last
meal for analysis of ammonia, urea and uric acid in plasma. Fish were subsequently dissected for
morphometric measurements. Another ﬁve ﬁsh per replicate were taken for whole body composition.
Rigor index and muscle pH were measured in six ﬁsh per treatment at 0, 2, 2 and 24 h after slaughter.
Survival rate was high (> 90%) and not affected by diet. Feed intake (values given in ﬁgures only),
expressed as g ﬁsh/day, declined signiﬁcantly (p < 0.05) in the group with 39% dietary PT73 (THR)
after the ﬁrst 2 weeks. Final body weight of trout fed diets with 6.6% and 13.1% PT73 (THR) (434
and 398 g, respectively) did not differ from the control group (409 g); however, 26.3% and 39.4%
PT73 (THR) led to a signiﬁcant growth depression (350 and 228 g, respectively). Feed to gain ratio
was signiﬁcantly reduced in groups fed diets with 13.1–39.4% PT73 (THR) (1.09, 1.09, 0.98, 0.93 and
0.62 for the diets with 0%, 6.6%, 13.1%, 26.3% and 39.4% PT73 (THR), respectively). Protein
efﬁciency ratios followed similar trends.
There were no signiﬁcant differences between groups for the viscerosomatic index, gutting index
and liver to body weight ratio or in plasma metabolites.
For the post-mortem muscle characteristics, only those groups having similar ﬁnal mean body
weights (control, 6.6% and 13.1% PT73 (THR)) were retained. Muscle pH changes followed similar
patterns in all groups. Rigor index was initiated earlier in trout fed the ﬁshmeal-based diet and was
slower in trout fed the diets containing PT73 (THR), especially at 13.1% PT73 (THR).
As regards whole body composition, trout fed the 39.4% PT73 (THR) diet had a signiﬁcantly
decreased protein (15.9%), fat (5.9%) and energy content (6.4 KJ/g) as compared to the other
groups (control group: 17.0% CP, 10.4% fat and 8.3 KJ/g). Protein and energy retention were
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signiﬁcantly higher in trout fed the control diet and the diet with 6.6% PT73 (THR) than in trout fed
the other experimental diets (protein retention for the groups with 0%, 6.6%, 13.1%, 26.3% and
39.4% PT73 (THR) 36%, 34%, 31%, 30% and 18%, and energy retention 58%, 55%, 46%, 39% and
20%, respectively).
Conclusions on salmonids
The results of the feeding study with PT73 (THR) in rainbow trout indicate that a concentration of
13% in the diet does not adversely affect performance of salmonids.
3.5.3. Product quality
Morning milk samples were obtained in the study with dairy cows fed with PT73 (TM). Samples of
milk (2.5 L) were pooled from four cows, homogenised and pasteurised before a taste panel
evaluation (N = 12). The overall score of sensory characteristics derived from 18 different descriptors
(e.g. sweet, sour, bitter). In the 8-point scale used, an overall score of 6 describes milk of a sufﬁcient
quality. Scores observed in this study varied between 6.03 and 6.41, with no signiﬁcant differences
between treatment groups. There were neither obvious off-ﬂavours nor defects noticed by any of the
panel members.
Sensory properties of meat from samples (m. longissimus lumborum) of seven random pigs of the
control group and of the group with 12% dietary PT73 (THR) from the experiment described above
(Section 3.5.2.4, study 2) were evaluated (23 sensory attributes, divided into the categories
appearance, odour, texture, taste and aftertaste) by a Taste Panel according to ISO standard 6564
(1985). For all attributes, no signiﬁcant differences between the meat from control pigs and the 12%
PT73 (THR) group were found.
Although sensory attributes can be quite subtle, it is probable that the results seen with PT73
(THR) would also apply to comparable diets with PT73 (TM).
3.6. Toxicological characterisation
The genotoxicity/mutagenicity studies and the subchronic oral toxicity studies were performed with
one of the pilot scale batches while the oral prenatal developmental study was made with one of the
industrial scale batches of PT73 (TM). Duplicate studies were also made with the former biomass PT73
(THR).
3.6.1. Genotoxicity and mutagenicity studies
As the bacterial biomass PT73 (TM) is an insoluble material, aqueous extracts were used for in vitro
genotoxicity tests. Suspensions of PT73 (TM) in saline solution (bacterial test) or in culture medium
without serum (tests in mammalian cells) were sonicated for 15 min and incubated for 24 h at 37°C
under agitation. These extracts were centrifuged for 20 min at 1,200g. The supernatants were
sterilised by passage through a micropore ﬁlter (0.45 lm). The initial suspensions used to prepare the
extracts tested in the three genotoxicity studies had different concentrations: 10 mg/mL, 50 mg/mL
and 12.5 mg/mL for the bacterial test, the chromosome aberration test and the gene mutation test,
respectively. The nominal concentration of each ﬁnal extract was considered equivalent to the
concentration of the initial suspension and the tested concentration levels reported in the studies
reﬂect this nominal concentration.
3.6.1.1. Bacterial reverse mutation assay
An aqueous extract of PT73 (TM) was tested at ﬁve concentrations ranging from 62 to 5,000
lg/plate in Salmonella Typhimurium strains TA1535, TA1537, TA100, TA98 and in E. coli WP2uvrA, in
the absence and presence of a liver fraction of Aroclor 1254-induced rats for metabolic activation
(S9-mix) using the plate incorporation method, in compliance with OECD guideline 471. No cytotoxicity
was reported. The test item was not mutagenic under the conditions employed in this study while the
positive controls gave the expected increase in the mean number of revertant colonies.
3.6.1.2. In vitro mammalian chromosome aberration test
An aqueous extract of PT73 (TM) was tested in a chromosomal aberration study in Chinese
hamster ovary cells, in both the absence and presence of a metabolic activation system (S9-mix) in
compliance with OECD guideline 473 (revision 1997). Two independent chromosomal aberration tests
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were conducted. In the ﬁrst test, a 4-h treatment time and an 18-h harvesting time were applied
(pulse treatment). Three concentrations (1,250, 2,500 and 5,000 lg/mL) were tested with and without
metabolic activation system (S9-mix). The test substance was slightly cytotoxic to the cells at the
highest dose level in the presence of metabolic activation system. In the second test, the pulse
treatment schedule in the presence of S9-mix was applied and the tested concentrations were 3,000,
4,000 and 5,000 lg/mL. In the absence of S9-mix, the treatment time was 18 h (continuous
treatment) and three dose levels of the test substance (3,000, 4,000 and 5,000 lg/mL) were
analysed. The pulse treatment with S9-mix was not cytotoxic to the cells at any dose levels, while the
continuous treatment without S9-mix was slightly cytotoxic to the cells at the mid dose and clearly
cytotoxic at the highest dose level (5,000 lg/mL). In both the ﬁrst and second chromosomal
aberration test, the test substance did not induce a statistically signiﬁcant increase in the number of
aberrant cells at any of the concentrations and time-points analysed. The positive control substances
induced the expected statistically signiﬁcant increases in the incidence of structural chromosomal
aberrations.
3.6.1.3. In vitro gene mutation test
An aqueous extract of PT73 (TM) was tested for its potential to induce gene mutations at the
TK-locus of cultured mouse lymphoma L5178Y cells, in both the absence and the presence of a
metabolic activation system (S9-mix) in compliance with OECD guideline 476. Two assays were
conducted. In the ﬁrst assay, single cultures were treated for 24 and 4 h in the absence and presence
of S9-mix, respectively. In the second assay, single cultures were treated for 24 and 4 h in the
absence of S9-mix. The highest concentration of the extract of PT73 (TM) evaluated for mutagenicity
in both the absence and presence of S9-mix was equivalent to 5,000 lg/mL. The extract of PT73 (TM)
was slightly toxic to the cells, especially in the absence of S9-mix after extended (24 h) treatment. At
the highest concentration tested the relative total growth (RTG) was 46% and 77% in the absence
and presence of S9-mix, respectively. In both the absence and presence of S9-mix, no relevant
increases in the mutant frequency were observed at any concentration, while the positive controls
performed as expected.
Comparable studies with the PT73 (THR) biomass also gave negative results.
3.6.2. Toxicity studies with laboratory animals
3.6.2.1. Repeat dose subchronic oral toxicity study
Study 1
PT73 (TM) was administered in the diet to groups of 10 Wistar rats of each sex for 90 days at
concentrations of 0%, 5%, 10% or 20%, the highest dose equivalent to 10.1–10.9 g/kg bw per day. The
proteinaceous test article (partly) substituted casein in the diet. The study was conducted according to
OECD guideline 408. Observations included daily clinical inspection, weekly neurobehavioral testing,
ophtalmoscopy, body weight, food and water consumption, haematology, clinical chemistry, urinalysis
including renal concentration test, oestrus cyclicity, sperm analysis, organ weights and gross and
histopathology in the control and high-dose groups, and grossly observed lesions in the intermediate
dose groups.
No treatment-related effects were found in clinical and neurobehavioral observations, food
consumption, gross pathology, oestrus cyclicity, sperm analysis.
Effects observed included occasional increase in water intake in mid- and high-dose males, a
downward trend in thrombocytes in females, prolonged prothrombin time in all dosed male (but within
historical control range), increase in total white blood cells and monocytes in high-dose females, lower
percentage of lymphocytes and increase in neutrophils in the high dose (both sexes). Urine production
showed an upward trend in males.
In relative and absolute organ weights increase was found in kidney, liver and spleen notably in the
high-dose females, and in clinical chemistry various blood parameters were increased or decreased.
Notably cholesterol and phospholipids were decreased (males dose related, females high dose only)
while alanine transaminase (ALAT) was increased in high-dose females. In histopathology, a slight
increase in focal mononuclear aggregates was observed in the liver of all treated males and
hepatocellular vacuolation was slightly increased in all treated females and high-dose males. Increased
brown pigment was observed in the spleen of all treated animals, identiﬁed as a preservation
(formalin) artefact, the relation with treatment being unknown.
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Study 2
A second repeated dose oral toxicity study was conducted to provide evidence on the possible
mechanism of the observed generic effects. Three groups of 15 male Wistar WU (Crl:WI(WU),
outbred) rats received control feed, PT73(TM) at 5% or 15%. Observations were conducted similarly
to those described for previous studies and the new study conﬁrmed those effects observed previously
(prolonged prothrombin time, lower levels of plasma cholesterol and phospholipids, increased
aspartate transaminase (ASAT) or alkaline phosphatase (ALP) activity and increased kidney weights).
Some of the adverse effects observed in this study and the previous one might be compatible with
the absorption of endotoxins (LPS) from the intestinal tract. The levels of LPS in the diets (EU/g) were
566–803 for the control, 36,100–27,000 for the 5% group and 109,000–119,000 for the 15% group.
Despite the sensitive detection limit for endotoxins (< 66 ng/mL), LPS was not detected in the serum
of any rat after receiving feed containing 5% or 15% PT73 (TM) for 4 or 13 weeks. Also, there were
no relevant changes in ﬁrst-phase reactants (C-reactive protein, haptoglobin). It was concluded that
orally administered endotoxins did not become systemically available.
The FEEDAP Panel concludes that the new data provide sufﬁcient evidence that the generic effects
seen with PT73 (TM) cannot be ascribed to circulating endotoxins or their derivatives.
Study with PT73 (THR)
An earlier study made with the biomass PT73 (THR) at levels of 3%, 8% and 15% also showed many
of the generic effects observed in the studies done with the current product (PT73 (TM)), such as the
increase in prothrombin time, increase in water intake and urine production, decrease in cholesterol and
phospholipids, increase in liver, spleen and kidney weight, and no associated histopathological ﬁndings.
Thrombocyte counts were signiﬁcantly lower than controls in the high-dose group of both sexes and in
mid-dose males. Prothrombin time was signiﬁcantly increased in high-dose males. Serum alkaline
phosphatase was increased in both sexes at mid and high doses. Cholesterol was signiﬁcantly decreased
in male mid- and high-dose groups, and phospholipids were reduced in the high-dose males only.
Urinary volume was increased in the male mid- and high-dose groups. At necropsy, relative weights of
adrenals and kidneys were signiﬁcantly increased in mid- and high-dose males. Relative liver weights
were increased in all male groups and the female high-dose only. Absolute and relative uterus weights
were increased in high-dose females.
Discussion on Repeated dose oral toxicity studies
Many of the effects seen in the subchronic studies with PT73 (TM) were also seen with other
bacterial biomass products, both the earlier form of this product (PT73 (THR)) and related products,
also produced by fermentation with E. coli, PL73 (LM) and PL73 (LYS) (EFSA FEEDAP Panel, 2017).
Since they are reproducibly related to exposure to these products it may be concluded that those
effects are causally related to treatment. The main effects seen were an increase in water intake and
liver weight, reduction of cholesterol, phospholipids and prolonged blood coagulation time.
Water intake was noted to be increased by treatment of rats with PT73 (TM) and for all other rat
studies with biomasses. This effect at high doses is most likely explained by the higher intake of
electrolytes. Renal weight changes, changes in faecal consistency and an increase in urine output may
also be associated with such an effect (Lina and Kuijpers, 2004).
Serum cholesterol and phospholipid levels were decreased in dose dependent way in male rats (in
females at the highest dose only) fed PT73 (TM). A similar ﬁnding is seen with related biomasses
(PT73 (THR), PL73 (LM) and PL73 (LYS)) in rats. This reduction in cholesterol is attributed to the
dietary compositional changes caused by the use of high levels of bacterial biomass. Although diets for
rat studies were adjusted to be isoproteic, animal proteins are generally considered to be more
cholesterolaemic than other proteins. The hypercholesterolaemic effect of casein/casein-based diets,
compared to diets containing other sources of proteins, in rats and other species such as hamsters,
rabbits, mice, pig and humans has been reported in numerous studies (Potter, 1995; Balmir et al., 1996;
Morita et al., 1997; Nagaoka et al., 1999; Greaves et al., 2000; Tomotake et al., 2000; Ascensio et al.,
2004; Esteves et al., 2011). Thus, the substitution in the experimental rat diets of casein by a protein
of non-animal origin may sufﬁce to explain the decreased blood cholesterol and phospholipids levels
observed in laboratory animals fed diets containing PT73 (TM).
Prothrombin time was prolonged and thrombocyte counts reduced by treatment with PT73 (TM)
and by all the other related biomass products. Although nutritional studies have occasionally shown
effects of diet on one or other of the above, there is insufﬁcient evidence to conclude that these are
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nutritionally related rather than speciﬁc effects of the biomass. Although the effects are small, they are
reproducible and must be considered adverse effects of treatment. Without knowing the origin of
these effects, it cannot be identiﬁed whether or not they are relevant to consumer or target species
risk.
Liver weight and relative liver weight are increased by treatment with PT73 (TM) and similar
ﬁndings are reported for PT73 (THR), PL73 (LM) and PL73 (LYS). Histologically, the enlargement was
associated with increased incidence of mononuclear cell aggregates. Such changes are normally
present in rats but were increased by treatment. The histological and weight changes were not
associated with a pattern of enzyme/clinical biochemistry changes normally associated with hepatic
damage but some such changes (ALAT increased in high-dose females) were observed. Although the
applicant suggests that the liver weight increase was due to increasing levels of ammonium and CP,
there is no convincing evidence from other studies of dietary variation to support this hypothesis. As
such the safety for both the consumer and target species of incorporating PT73 (TM) or any
E. coli-derived biomass in feed cannot be sufﬁciently established from the available data.
3.6.2.2. Prenatal developmental toxicity
PT73 (TM) was included in the feed of groups of 24 mated female rats from day 0 to day 21 at
concentrations of 0%, 4.9%, 9.8% and 19.6%. A reference control group was also included receiving
basal diet plus 1.3% (NH4)2SO4 in order to match the increased ammonium level in the high dose.
Each rat was monitored daily; body weight and food intake were monitored regularly throughout
gestation. Females were killed on day 21 and subject to gross necropsy with detailed examination of
the uterus and contents. Half of the fetuses were examined for soft part abnormalities and the
remainder for skeletal abnormalities. These examinations were carried out blind.
There were no effects of treatment on body weight or food intake of females. The number of
females apparently pregnant was 17, 21, 22, 19 and 22 of control, low, mid, high and reference group
respectively, but one high dose and one reference control female had no viable fetuses. No differences
were observed between groups in gestation index, fecundity index, corpora lutea, implantation sites,
pre- and post-implantation loss, live and dead fetuses, resorptions or sex ratio. External fetal and
placental observations and weights did not reveal any treatment-related effects. No treatment-related
effects were observed on visceral malformations, anomalies and variations, and on skeletal
malformations, anomalies, variations and retardations.
Similar ﬁndings were observed with the former biomass PT73 (THR).
3.6.3. Conclusions on toxicological studies with PT73 (TM)
The genotoxicity studies conducted provide sufﬁcient reassurance of the lack of genotoxicity of
PT73 (TM) and leave no concerns in this respect for target species, consumer or user safety.
Additionally, the studies conducted on fetal development demonstrate no evidence of adverse effects
on the offspring; thus, there are no speciﬁc concerns regarding effects on fetal development.
The 90-day studies conducted with PT73 (TM) showed several reproducible effects, which were
reduced cholesterol and phospholipid levels, increased water intake and liver weight (one study) and
extended coagulation time. Of these, the effects on liver and coagulation time were considered by the
Panel to be both adverse and unexplained.
3.6.4. Toxicological studies with antifoaming agent
During the manufacturing process, an antifoaming agent is used. The highest dose of the
antifoaming agent tested (1,000 mg/kg in feed or 94 mg/kg bw per day) in a 28-day rat study showed
no adverse effects. A 10% inclusion level in complete feed would result in a concentration of
1,500 mg/kg feed. This would correspond to an exposure of animals of approximately 23, 45 and
68 mg/kg bw of salmonids, dairy cows and pigs, respectively. The quantitative contribution of the
antifoaming agent to the diet is not considered to represent a risk and is not further considered in this
assessment.
3.7. Safety for the target species
The two products PT73 (TM) and PT73 (THR) are considered sufﬁciently similar to allow the use of
the studies performed with either product for the assessment of PT73 (TM).
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From the studies with dairy cows, pigs for fattening and rainbow trout it is concluded that PT73
(TM) can be used as any other protein-rich feed material in diet formulation when the guidelines for
nutrition and the chemical composition and nutritive value of PT73 (TM) are properly taken into
account. The study in dairy cows support the proposal of the applicant that inclusion of 8% PT73 (TM)
of feed dry matter (~ 7% in complete feed) is safe for dairy cows. This value could be extended to
other ruminants (from the beginning of rumination). Complete feed for pigs for fattening may contain
up to 10% PT73 (TM). From the data obtained in an 84-day study with PT73 (THR) in rainbow trout, it
is concluded that PL73 (TM) is safe for salmonids up to a dietary concentration of 13%.
Based on the studies on the inﬂuence of PT73 (TM) and PT73 (THR) on the sensory characteristics
of milk and pork, the FEEDAP Panel concludes that an inﬂuence of PT73 (TM) up to the levels
considered safe in the diet would not inﬂuence the sensory quality of tissues and products of animals.
3.8. Safety for the consumer
For animal feed ingredients or additives, assessment of the safety for the consumer is based upon
the toxicological data and the relevance of those data to consumer exposure. The toxicological data
indicate effects of PT73 (TM) on blood coagulation and liver which are considered to be adverse and
which may occur in the target species following use of the product in animal feed. Since the causative
agent(s) and mechanism(s) of these effects are unknown, there is no way of determining whether
residues exist in animal products sufﬁcient to cause similar effects in consumers. As a consequence,
the FEEDAP Panel is unable to conclude on the safety for the consumer of products derived from
animals receiving feed containing PT73 (TM).
3.9. Safety for the user
All the studies performed to assess the safety for the user were done with PT73 (THR). However,
considering the similar production and composition, the FEEDAP Panel considers that the hazard for
the user would not be signiﬁcantly different for PT73 (TM).
3.9.1. Effects on eyes and skin
PT73 (THR) was tested in three rabbits for acute dermal irritation potential following OECD
guideline 404. Since no effects were observed, the product is classiﬁed as not irritating to the human
skin.
PT73 (THR) was tested in three rabbits for acute eye irritation potential according to OECD
guideline 405. Effects on the conjunctiva were seen initially but these had cleared by 7 days after
exposure. Based on the results of this study the product is classiﬁed as not irritating to the human
eyes.
Although no data are provided on sensitisation potential the applicant states, the product to be
both a respiratory and a dermal sensitiser.
3.9.2. Effects on the respiratory system
Due to the proteinaceous nature of the product, it should be considered as a respiratory sensitiser.
An acute inhalation toxicity study according to OECD guideline 403 was performed on a group of 5
rats of each sex was exposed to PT73 (THR) nose only for 4 h at a concentration of 5.25 g/m3. Some
slight breathing difﬁculties were seen during exposure and the general condition of animals was below
normal for 1 day afterwards but had returned to normal by this time without any other signs of
adverse effect or any mortality. No effects of treatment were seen at necropsy. The study conducted
would probably not detect the respiratory inﬂammation effects typical of LPS and thus such effects in
users cannot be excluded. Considering the levels of LPS present in the product (up to 1 9 106 EU/g),
the Panel considers that any exposure to dust represents a serious risk to users.
3.9.3. Conclusions regarding user safety
PT73 (TM) is not considered a skin/eye irritant but should be considered as a potential skin and
respiratory sensitiser. The FEEDAP Panel considers that due to the endotoxin content any exposure of
users to dust from the product via the inhalation route should be considered a serious risk.
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3.10. Potential environmental impact
The applicant provided data demonstrating that the PT73 (TM) product does not contain viable
cells of the production strain E. coli FERM BP-10942. The heating and the inactivation conditions
described in the dossier are considered to be efﬁcient so that no viable production strain cells would
be present in the ﬁnal product.
No full-length antibiotic resistance gene sequences or other sequences of concern remained in the
production strain and no DNA fragments of sufﬁcient size to encode a gene were detected. Therefore,
no environmental impact from the use of this product is expected regarding the recombinant DNA
sequences possibly remaining in the product.
The FEEDAP Panel considers that substitution of PT73 (TM) for other protein-rich feed materials will
not adversely affect the environment.
4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation9 and Good Manufacturing
Practice.
5. Conclusions10
The recipient organism E. coli MG 1655 is considered to be safe. The traits introduced in the
production strain E. coli FERM BP-10942 are mainly limited to the overproduction of threonine. No full-
length antibiotic resistance gene sequences or other sequences of concern remained in the production
strain. In conclusion, the FEEDAP Panel did not identify risks for human and animal health or the
environment from the heat-inactivated biomass, regarding the genetically modiﬁed strain from which it
is made.
The proposed recommended use level for dairy cows (8% PT73 (TM) of feed DM (~ 7% in
complete feed)) and salmonids (13%) is considered safe for these target animals. The conclusion form
dairy cows could be extended to other ruminants (from the beginning of rumination). Complete feed
for pigs for fattening may contain up to 10% PT73 (TM).
The toxicological data indicate effects of PT73 (TM) on blood coagulation and liver, which are
considered to be adverse. Since the causative agent(s) and mechanism(s) of these effects are
unknown, there is no way of determining whether residues exist in animal products sufﬁcient to cause
similar effects in consumers. As a consequence, the FEEDAP Panel is unable to conclude on the safety
for the consumer of products derived from animals receiving feed containing PT73 (TM).
PT73 (TM) is not considered a skin/eye irritant but should be considered as a potential skin and
respiratory sensitiser. The FEEDAP Panel considers that due to the endotoxin content any exposure of
users to dust from the product via the inhalation route should be considered a serious risk.
The FEEDAP Panel considers that substitution of PT73 (TM) for other protein-rich feed materials will
not adversely affect the environment.
6. Recommendation
Since the risks identiﬁed do not relate to the genetic modiﬁcation but to the product itself
(biomasses derived from fermentation with E. coli and potentially other Gram negative bacteria), the
Panel recommends that similar non-genetically modiﬁed products used as feed materials should also
be assessed for safety.
Documentation provided to EFSA
1) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). April 2008.
Submitted by Ajinomoto Eurolysine S.A.S.
9 OJ L 35, 8.2.2005, p. 1.
10 This section has been amended following the conﬁdentiality claims made by the applicant on the basis of Article 30(1) of
Regulation (EC) No 1829/2003.
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2) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information. March 2012. Submitted by Ajinomoto Eurolysine S.A.S.
3) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information. July 2012. Submitted by Ajinomoto Eurolysine S.A.S.
4) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information. February 2013. Submitted by Ajinomoto Eurolysine S.A.S.
5) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information. April 2013. Submitted by Ajinomoto Eurolysine S.A.S.
6) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information June 2014. Submitted by Ajinomoto Eurolysine S.A.S.
7) Application for authorisation of the dried killed bacterial biomass PT73 (TM) intended to be
placed on the market as feed material, by-product of the production of L-threonine by
fermentation using the strain E. coli K12 FERM BP-10942 (FERM BP-10942). Supplementary
information. October 2016. Submitted by Ajinomoto Eurolysine S.A.S.
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Abbreviations
ALAT alanine transaminase
ALP alkaline phosphatase
ANOVA analysis of variance
ASAT aspartate transaminase
bw body weight
CFU colony forming unit
CP crude protein
DM dry matter
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GM genetically modiﬁed
LOQ limit of quantiﬁcation
LPS lipopolysaccharides
LSD least signiﬁcant difference
MIC minimum inhibitory concentration
NEL Net energy for lactation
OECD organisation for economic co-operation and development
PCB polychlorinated biphenyl
PCR polymerase chain reaction
RH relative humidity
RNA ribonucleic acid
RTG relative total growth
TMR total mixed ration
UV ultraviolet
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